Company Research Report: Twist Bioscience
Company Overview
- Name: Twist Bioscience
- Mission: Enable researchers across scientific disciplines to achieve groundbreaking discoveries, making the world safer, healthier, and more sustainable through synthetic DNA tools.
- Founded By: Emily Leproust, CEO and Co-Founder
- Key People:
- Emily Leproust, PhD - CEO and Co-Founder
- Patrick Finn - President and Chief Operating Officer
- Adam Laponis - Chief Financial Officer
- Nicole Moreno - Senior Vice President of Sales and Support
- Siyuan Chen - Chief Technology Officer
- Paula Green - Senior Vice President of Human Resources
- Mike Fero - Chief Information Officer
- Mark Buck - Senior Vice President of Operations
- Bill Banyai, PhD - Senior Vice President of Advanced Development and General Manager, Data Storage
- Angela Bitting - Chief ESG Officer, Senior Vice President of Corporate Affairs
- Dennis Cho - Chief Legal Officer and Corporate Secretary
- Headquarters: 681 Gateway Blvd, South San Francisco, CA 94080
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: Developing a proprietary semiconductor-based synthetic DNA manufacturing process that enables high-throughput synthesis, synthetic DNA tools, and biological innovations.
Products
- Genes: Customizable Gene Synthesis solutions, offering precision and scalability for various research needs.
- Libraries: High-diversity variant libraries for more effective genomic and antibody screens.
- Next-Generation Sequencing (NGS): Superior target enrichment solutions, providing high-confidence variant detection and exceptional coverage.
- Oligo Pools: High-uniformity and low-error rate oligos for a range of applications.
- Synthetic Controls: Standards for assay development including synthetic RNA and DNA controls.
- Antibody Services: Full suite of services for discovery and development of antibodies.
Key Features of Products
- Gene Synthesis:
- Gene Fragments: Delivered as linear fragments ranging from 0.3 kb to 5.0 kb.
- Clonal Genes: Provided in the vector of choice, with customization options for length and yield.
- High-Quality: High-throughput, scalable, and affordable gene manufacturing with low error rates.
- Variant Libraries:
- Combinatorial and Site Saturation Variants: For comprehensive screening and protein engineering.
- High Diversity: Up to 10^10 unique variants assured precision in experimental research.
- NGS Target Enrichment Panels:
- Customizable with high fidelity probes and scalable panel sizes.
- Rapid turnaround times and precision in variant detection.
- Oligo Pools:
- Ability to synthesize pools containing thousands of custom sequences.
- Precision synthesis up to 300nt, high uniformity and data confidence.
Recent Developments
- Partnership with MedGenome: Established HOPE for Rare Diseases Program in India to provide discounted whole exome sequencing for economically disadvantaged families.
- Advancements in Multiplexed Gene Fragments: Expanded offering to provide pooled dsDNA synthesis up to 500bp, facilitating more efficient high-throughput screening processes.
- Expansion in Synthetic Viral Controls: Enhanced portfolio to cover a range of pathogens, with flexible and safe assay-ready control configurations.
New Products and Features
- MRD Rapid 500 Panel: Launched to monitor minimal residual disease in a scalable manner with rapid turnaround of custom design panels.
- Advanced NGS and Synthetic Biology Tools: Developed applications for cancer research and clinical oncology. These tools support target identification, therapeutic development, and diagnostic monitoring.
Partnerships
- Biopharma Collaborations: Collaborating with industry players for advanced therapeutic discovery and development through antibody libraries and discovery services.
- NGS ProLab and Channel Partners: Expanding reach through strategic alliances and distribution channels.
Conclusion
Twist Bioscience stands out as a leader in synthetic DNA manufacturing, providing cutting-edge products and solutions to enable a wide array of scientific research and discovery. Their focus on partnerships and technological advancements ensures they remain at the forefront of the bioscience sector.